Literature DB >> 18033958

Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans.

Karl Georg Haeusler1, Wolf U H Schmidt, Fabian Föhring, Christian Meisel, Thomas Helms, G Jan Jungehulsing, Christian H Nolte, Katrin Schmolke, Brigitte Wegner, Andreas Meisel, Ulrich Dirnagl, Arno Villringer, Hans-Dieter Volk.   

Abstract

BACKGROUND: We have recently shown that ischemic stroke causes a stress-mediator-induced long-lasting immunodepressive state in mice.
METHODS: Using head magnetic resonance imaging and standardized immunoassays, we prospectively investigated whether poststroke immunodepression is also seen in humans.
RESULTS: Compared to healthy volunteers (n = 30), a rapid depression of lymphocyte counts and a functional deactivation of monocytes and T helper type 1 cells was observed in acute stroke patients (SP; n = 40). Immunodepression was more pronounced in patients with severe clinical deficit or large infarction. On admission the combination of monocytic tumor necrosis factor alpha release ex vivo and the National Institute of Health Stroke Scale score were the best predictors for nosocomial infection, preferentially affecting older SP.
CONCLUSION: Our data provide evidence for an immediate suppression of cell-mediated immune responses after ischemic stroke in humans. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 18033958     DOI: 10.1159/000111499

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  80 in total

Review 1.  The immunology of acute stroke.

Authors:  Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp
Journal:  Nat Rev Neurol       Date:  2012-06-05       Impact factor: 42.937

2.  [Management of acute ischemic stroke].

Authors:  C H Nolte; M Endres
Journal:  Internist (Berl)       Date:  2012-05       Impact factor: 0.743

Review 3.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

4.  Autoimmune responses to brain following stroke.

Authors:  Kyra Becker
Journal:  Transl Stroke Res       Date:  2012-04-05       Impact factor: 6.829

5.  Lymphocyte-to-monocyte ratio on day 7 is associated with outcomes in acute ischemic stroke.

Authors:  Min-Gyu Park; Min-Kyeung Kim; Song-Hwa Chae; Hyung-Keun Kim; Junhee Han; Kyung-Pil Park
Journal:  Neurol Sci       Date:  2017-10-30       Impact factor: 3.307

6.  Risk of Acute Stroke After Hospitalization for Sepsis: A Case-Crossover Study.

Authors:  Amelia K Boehme; Purnima Ranawat; Jorge Luna; Hooman Kamel; Mitchell S V Elkind
Journal:  Stroke       Date:  2017-02-14       Impact factor: 7.914

Review 7.  A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion.

Authors:  Ligen Shi; Marcelo Rocha; Rehana K Leak; Jingyan Zhao; Tarun N Bhatia; Hongfeng Mu; Zhishuo Wei; Fang Yu; Susan L Weiner; Feifei Ma; Tudor G Jovin; Jun Chen
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-07       Impact factor: 6.200

8.  Usefulness of serum procalcitonin levels for the early diagnosis of stroke-associated respiratory tract infections.

Authors:  Andreas Hug; Bettina Mürle; Alexander Dalpke; Markus Zorn; Arthur Liesz; Roland Veltkamp
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

Review 9.  The immune system in stroke: clinical challenges and their translation to experimental research.

Authors:  Craig J Smith; Catherine B Lawrence; Beatriz Rodriguez-Grande; Krisztina J Kovacs; Jesus M Pradillo; Adam Denes
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-15       Impact factor: 4.147

10.  Functional status of peripheral blood T-cells in ischemic stroke patients.

Authors:  Antje Vogelgesang; Verena E L May; Uwe Grunwald; Maren Bakkeboe; Soenke Langner; Henry Wallaschofski; Christof Kessler; Barbara M Bröker; Alexander Dressel
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.